Several embodiments disclosed herein relate to the delivery of therapeutic nucleic acids to an ocular tissue in order to provide a therapeutic effect to reduce symptoms of or otherwise alleviate an ocular disorder. In particular embodiments, plasmid DNA is delivered to the cells of the trabecular meshwork in order to ameliorate increasing intraocular pressure. Devices and systems to accomplish this delivery are also disclosed.

This application is related to a head-mounted display system and related methods for entertainment, diagnostics, and treatment. The HMD includes various sensors and tools to take physical measurements, perform physical procedures, adjust physical conditions, or manipulate digital data. In some embodiments, the HMD produces different types of sensory stimuli, such as releasing or filtering certain compounds in liquid or aqueous forms in the space near the HMD, or adjusting different physical features of the space near the HMD, such as temperature and flow, to enhance the augmented or virtual reality environment being displayed. In some embodiments, the HMD performs regular monitoring, a specific examination, a surgical intervention, or other care procedures on the eyes automatically or in conjunction with a device of an eye care professional across a computer network to care for the user's eyes in real time or on an ongoing basis.

This application is related to a head-mounted display system and related methods for entertainment, diagnostics, and treatment. The HMD includes various sensors and tools to take physical measurements, perform physical procedures, adjust physical conditions, or manipulate digital data. In some embodiments, the HMD produces different types of sensory stimuli, such as releasing or filtering certain compounds in liquid or aqueous forms in the space near the HMD, or adjusting different physical features of the space near the HMD, such as temperature and flow, to enhance the augmented or virtual reality environment being displayed. In some embodiments, the HMD performs regular monitoring, a specific examination, a surgical intervention, or other care procedures on the eyes automatically or in conjunction with a device of an eye care professional across a computer network to care for the user's eyes in real time or on an ongoing basis.

Injection devices for delivering pharmaceutical compositions into the eye are described. Some devices include a resistance component for controllably deploying an injection needle through the eye wall. The resistance component may be disposed on a removable injector attachment or on a portion of the injection device housing. Other devices may include a filter for the removal of air, infectious agents, and/or other particulate matter from the composition before the composition is injected into the eye. Related methods and systems comprising the devices are also described.

An eyedrop bottle holder with resilient arms formed from an inverted U-shaped band made from resilient injection molded plastic. The top middle portion of the inverted U-shape band includes a centrally located opening through which the top (dispensing portion) of a standard eyedrop bottle containing eyedrop solution may be positioned and held. The right and left arms of the U-shape band each terminate in an outwardly disposed J-shape foot, the underside of which is covered by a soft rubber-like pad. When a user inserts a standard eyedrop bottle into the holder, the dispensing tip of the eyedrop bottle may be positioned in close proximity to the user's eye. The user may cause his or her eye lid to remain open by using the fingers of one hand to squeeze the right and left arms of the holder together, then placing the pad of one arm on the upper ridge of the orbital eye socket and the pad of the second arm on the lower ridge of the orbital eye socket. Releasing the arms causes the skin of the user's upper and lower eyelids to be spread apart from each other and remain spread during an eyedrop solution dispensing event. The eyedrop bottle is retained within a housing that includes an electromechanical assembly with a rotating cam that pushes on the side of the bottle until a predetermined amount of solution is dispensed. When a set amount of eyedrop solution has been dispensed, the assembly resets itself. An electronic sensor detects the passage of a drop of solution from the bottle and directs a reverse motion to the rotating cam. Tilt sensors assist the user in properly orienting the device for use. An adaptor may be used to accommodate non-standard sized eyedrop bottles.

A drug insert is configured for use with an implant. The implant is configured for insertion into a lacrimal canaliculus. The drug insert includes a drug core comprising a therapeutic agent and a polymer; and a sheath body comprising material substantially impermeable to the therapeutic agent, wherein the drug core is positioned within the sheath body. The sheath body is configured to provide an exposed end of the drug core that releases therapeutic agent to an eye when the drug insert is disposed within the implant and the implant is positioned in the lacrimal canaliculus. A distal end of the drug core is sealed with a medical-grade adhesive.

There is disclosed an eye-dropper positioning device (10) including a container (12) having at least a substantially transparent portion and defining an interior. The device (10) further includes a fluid (14) at least partially filling the interior of the container (12). The device (10) further includes a mirror assembly (16) located in the interior of the container (10). The mirror assembly (16) comprises at least one reflecting surface (20); and an orientating means (22) buoyantly supported by the fluid (14) and configured to substantially face the at least one reflecting surface (20) downwardly such that an image of an eye under the container (10) is reflected by the at least one reflecting surface (20) back to the eye through the substantially transparent portion of the container (10).

A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.

An ophthalmic infusion support and associated methods are shown. The ophthalmic infusion support devices include a base unit, a fixation device coupled to a bottom surface of the base unit, and an infusion tube holding device configured to hold a loop of an infusion tube at an angle projecting upward from a patient.

An eye drop applicator includes an applicator body with a top cavity, a bottom cavity, and a dispensing channel connecting the bottom cavity with the top cavity such that a fluid can selectively flow through the dispensing channel to the top cavity. The top cavity includes an opening at a top end of the applicator body, and the bottom cavity includes a bottom opening at a bottom end of the applicator body. The bottom cavity may receive a portion of an applicator container within the bottom cavity to assemble the eye drop applicator with the applicator container containing the fluid to be dispensed.